Our Services
HGS Consultancy provide a range of services that are designed to help pharmaceutical companies’ sales and marketing teams maximise their understanding and interaction with the modernised NHS and enable then to communicate with NHS customers in a more appropriate and commercially impactful way.
Which service is best for you?
The tabs below identify some of the common commercial issues for marketers and identifies the products and service offerings that can be used to overcome these issues. Click on the tabs for further details.
 |
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
- Need to plan effectively for product launch
- Poor uptake of in-market product by the NHS
|
|
|
|
|
|
 |
 |
 |
 |
 |
|
Philosophy
HGS Consultancy Limited managed entry strategies ensure that stakeholders are able to work together to plan together for the financial and service impact of the new chemical entity – enabling appropriate patients to benefit from the technological advance. We also work with clients to ensure “follow-on funding” and an expanded patient base in the years following launch
HGS Consultancy Limited is highly experienced in defining the optimum pathway for the successful managed entry of new products. Our process and reach through our PCO network database Accelerate® enables the right customer groups to be identified and their needs understood prior to launch – which means our client companies can align their communications and marketing strategies to fit.
Our managed entry programmes bring stakeholders together to discuss the likely response of the NHS to the new treatment, critically helping them understand the company’s expectations for the drug and how they might want to consider funding and service issues relating to the drug.
Managed Entry Stakeholders
HGS Consultancy Limited can establish the patient profile for the product and where it might fit within a NHS Trust, PCO or Joint Formulary.
HGS Consultancy Limited can define not only the business case, but also the commissioning process, the DoH framework and guidelines the product needs to address and how they will affect prescribing - both in a positive and negative way.
Most importantly, our experience of handling managed entry programmes, means we have the knowledge and confidence to weight this prescribing matrix and translate it into a practical, all encompassing launch programme - based on our “inside-out” knowledge of PCTs and the pharmaceutical industry.
MANAGED ENTRY PROGRAMMES
HGS Consultancy Limited is actively involved in shaping managed entry strategies for a number of pharmaceutical clients in the UK leading towards the production of innovative materials and resource to prepare NHS payors for the launch.
Market Environment Analysis
HGS have undertaken a number of ‘Market Environment Analysis’ for pharmaceutical clients based on specific disease areas. These reviews cover all of the macro environmental policies and drivers and enable the client to start their strategic planning with a clear insight into the current market.
Business Cases
HealthGain develop business cases to help clients work more effectively with commissioners in order to prepare for service and financial issues.
Prescribing Impact Resource Template - PIRT®
The template enables NHS organisations to plan for the managed introduction of products by providing answers to questions that cover commissioning, funding and clinical decision-makers.
The template outlines an approach for assessing the prescribing impact of a new drug in the local health economy. It will help the customer to consider the issues at local level in making decisions about what health care should be provided when resources are limited and services are under increasing pressure, when a new drug is launched. The template incorporates the views of local clinicians and recommendations made on the managed entry plan for prescribing of a new drug within the local health care system.
The template is divided into a number of sections. The first part is background to the disease area and the new drug, including the evidence and implications of using this therapy over current practice. The second part is resource assessment. In each NHS organisation a group of stakeholders should be identified to work together to put the case forward to the relevant committee. It is envisaged that the template would be completed at local level in target units/PCOs by the local Market Access team supported where appropriate by hospital representatives.
Prescribing Impact Team
This team helps prepare NHS customers to be able to understand where the NCE/NLI fits, the patient types, funding requirement, service issues and agree planned entry at local level.
The team provides facilitation, education and communication within the locality.
The target audiences are budget holders and budget managers i.e. PA’s and commissioners.
The people who make up this team have previous experience in the NHS such as pharmacists with business planning experience, or a background in NHS commissioning, business planning, service redesign etc.
Key Opinion Leader (KoL) Development – Making the Business Case
This enables KoLs to develop the rationale to budget managers to provide funding for new chemical entity or new licensed indication.
It is delivered as a one day programme or, can be included within an existing KoL meeting programme. It aims to provide
- An update on NHS financial management and pressures
- Inform on commissioning and budgetary mechanisms
- Present the clinical case in a meaningful way for commissioners
- Is instrumental in building a business case
- Provides D & T application training for clinicians
Drug & Therapeutics Committee Application Pack
This is for use by hospital representatives to aid with providing
- Clinical papers
- Patient profiles
- Financial Data
- Health economics benefits
- D & T templates – both paper and electronic versions to enable transfer of information to specific D & T application forms
Accelerating Formulary Uptake – Hospital representative training
To address the issue faced by clients whose representatives are able to get an application into a D & T Committee, only to find it gets deferred.
